Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Slides:

Advertisements

Similar presentations

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Advertisements

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

Introduction. Practical Perspectives in the Surgical Management of Parkinson Disease: LCIG.

Assessment and Monitoring Asthma and Clinical Action Plan

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Blood eosinophils as a biomarker in alpha 1 antitrypsin deficiency

Blood eosinophil count and exacerbation risk in patients with COPD

Moderate-to-Severe Asthma Management

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Practical Recommendations for COPD:

COPD by the Guidelines.

IL-12 and IL-23.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Alalia Berry, MD, William W. Busse, MD

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Clinical Review.

Stepping Up Asthma Control for Effective Management

The ABCs of Nitric Oxide in the Skin

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

New Insights Into Neurogenic Orthostatic Hypotension

Definitions: Seizure, Epilepsy, Epilepsy Syndrome

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

Complicated Cases in Ulcerative Colitis

Addressing Disease Burden in Asthma

When Would You Use Single Inhaler Triple Therapy in COPD?

Combination Inhaled Therapy in COPD: The Impact of Recent Data

VTE Treatment Conventional Approach

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.

Tackling Atopic Dermatitis

Advancing the Treatment of IBD With Biologics

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

What's New in Therapeutic Options for Moderate to Severe RA?

Advances in Severe Asthma Management

Long-Acting Agents in Severe COPD

Challenges in Severe Asthma

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison William Busse, MD, Geoffrey Chupp,

Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.

Achieving Asthma Control

Severe Asthma and Comorbidities

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Application of Biologics in IBD:

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Update on the Management of Atopic Dermatitis

Incorporating Prostacyclins Into Practice

Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome Sophia Kim, MD, Gautham Marigowda, MD, Eyal Oren, MD, Elliot.

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

The efficacy and safety of omalizumab in pediatric allergic asthma

Pathophysiologic Targets of Allergic Asthma

MS, Age, and Immune Function

Damal Kandadai Sriram, Govindaraj Gowri, Melvin George

Practical Recommendations for COPD:

Introduction Project At Crown Street Surgery:

Where Does Anticholinergic Therapy Fit in Moderate to Severe Asthma?

The Asthma Treatment Gap

Foundations of Asthma.

Foundations of Asthma.

Presentation transcript:

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma

Introduction

Introduction (cont)

Definition of Severe Asthma

Definition of Uncontrolled Asthma

Emerging Asthma Phenotypes

Goals of Asthma Management

Adults and Adolescents 12+ Years

What Is the Relationship of Blood Eosinophils to Severe Asthma Exacerbations?

Factors of Type 2 Inflammation

When to Consider Biologics?

Adverse Outcomes of Systemic Corticosteroids for Asthma

Why is it Important to Assess Inflammatory Phenotype on High-Dose ICS?

Adverse Outcomes from SCS: Long-Term Observational Study

Comorbidities as Part of the Severe Asthma Syndrome and OCS Side Effects

Factors to Predict Response to Biologics

Where Are We? Data From the UK General Population

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma (cont)

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Targets for Biologic Treatments of T2-Type Asthma

T2 Status and Exacerbation Rate

When to Consider Biologics?

GINA Severe Asthma Options: Indications for Biologics

Annual Exacerbation Rate Ratio (Benralizumab vs Placebo)

Which Biologic is Appropriate to Start First?

Conclusion

Abbreviations

Abbreviations (cont)